Penn trial finds semaglutide holds calorie intake down through 60 weeks
Subjective hunger and food-noise differences versus placebo faded by weeks 40 and 60 even as measured food intake stayed sharply lower.
PR
By Priya Raman · Science Reporter
Jul 21 03:00 ETSource: pennmedicine.org
The wire
- 01In 120 adults with overweight or obesity, those on weekly 2.4 mg semaglutide ate 24% to 30% fewer calories than placebo at laboratory test meals through week 60, published in the American Journal of Clinical Nutrition.
- 02Weight loss averaged 15.1% with semaglutide versus 3.4% with placebo, giving clinicians a counter-argument when patients say the drug has stopped working as hunger returns.
- 03Differences in self-reported hunger, appetite control and food preoccupation were no longer statistically significant by weeks 40 and 60; the trial enrolled 120 participants and included lifestyle counseling for both arms.
From the source
Read at pennmedicine.orgSemaglutide sustains lower calorie intake for more than a year
Penn Medicine researchers find semaglutide impacts remain, even as feelings of hunger gradually return.